Zoledronic Acid [For osteoporosis]: Brands, Price & Uses in Bangladesh

Zoledronic Acid [For osteoporosis] is a nitrogen-containing bisphosphonate given by intravenous (IV) infusion, indicated for the following osteoporosis-related uses:

Established / Approved Uses

• Treatment of postmenopausal osteoporosis — reduces the incidence of vertebral, hip, and non-vertebral fractures.
• Prevention of postmenopausal osteoporosis in women at risk of bone loss.
• Treatment to increase bone mass in men with osteoporosis.
• Treatment and prevention of glucocorticoid-induced osteoporosis in men and women expected to remain on long-term systemic corticosteroid therapy (≥7.5 mg/day prednisone equivalent for ≥12 months).

Important Note

This entry covers the lower-dose, infrequent (annual or less often) infusion regimen used specifically for osteoporosis. It is distinct from the higher-dose, more frequent regimen of the same molecule used for hypercalcemia of malignancy or bone metastases, which is not covered by this entry.

Dosing by Indication

Administration

• Administered as a single intravenous infusion over no less than 15 minutes, using a vented infusion line and a separate line from any other IV medication.
• Patients must be well hydrated before receiving Zoledronic Acid [For osteoporosis], especially the elderly and those on diuretics; a standard glass of water or two before infusion is generally advised as directed by the physician.
• Renal function (serum creatinine / creatinine clearance) must be assessed before every dose.
• Pre-existing hypocalcemia must be corrected, and adequate calcium (e.g. 500 mg/day or as advised) and vitamin D (e.g. 400–800 IU/day or as advised) supplementation should be ensured before and after infusion, particularly in the two weeks following the dose.
• A dental check-up is recommended before starting therapy in patients with risk factors for osteonecrosis of the jaw (see Precautions).

Renal Impairment

No dose adjustment is needed for mild-to-moderate renal impairment (creatinine clearance ≥35 mL/min). Use is contraindicated when creatinine clearance is below 35 mL/min or in acute renal impairment (see Contraindications).

Missed Dose

If a scheduled infusion is missed, it should be administered as soon as possible and the treatment schedule adjusted by the physician; the next dose should then be scheduled according to the original dosing interval from the date of the most recent infusion.

Common side effects of Zoledronic Acid [For osteoporosis] are usually related to the acute phase reaction following the first infusion and generally decrease with subsequent doses.

Very Common / Common

• Flu-like symptoms: fever, myalgia (muscle aches), arthralgia (joint pain), fatigue
• Headache
• Nausea, vomiting, diarrhea, abdominal pain
• Bone pain
• Injection/infusion-site reactions
• Mild, transient hypocalcemia

Less Common but Important

• Atrial fibrillation (reported in some studies; causal link not firmly established)
• Renal function abnormalities
• Osteonecrosis of the jaw (rare; see Precautions)
• Atypical femur fractures with long-term use (rare; see Precautions)
• Severe hypocalcemia (uncommon, more likely with untreated vitamin D deficiency or renal impairment)
• Uveitis, scleritis, or other ocular inflammation (rare)

Report any severe or persistent symptoms, especially jaw pain/swelling, unusual thigh/groin pain, or muscle cramps/tingling (signs of hypocalcemia), to your physician promptly.